MANTOVANI, ALBERTO
MANTOVANI, ALBERTO
Dipartimento di Scienze Mediche e Chirurgiche
Evaluation of ChatGPT as a counselling tool for Italian-speaking MASLD patients: assessment of accuracy, completeness and comprehensiveness
2024-01-01 Pugliese, N; Polverini, D; Lombardi, R; Pennisi, G; Ravaioli, F; Armandi, A; Buzzetti, E; Dalbeni, A; Liguori, A; Mantovani, A; Villani, R; Hassan, C; Valenti, L; Miele, L; Petta, S; Sebastiani, G; Aghemo, A
EVOLUTION OF LIVER FIBROSIS IN TYPE 2 DIABETIC PATIENTS WITH NAFLD IN A FOLLOW-UP STUDY: POSSIBLE HEPATOPROTECTIVE EFFECTS OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS
2023-01-01 Lombardi, R; Cespiati, A; Mantovani, A; Maffi, G; Francione, P; Cinque, F; Santomenna, F; Currà, J; Maffeis, C; Colecchia, A; Passigato, N; Ferrarese, A; Cusumanu, Cd; Villani, R; Orsi, E; Grancini, V; Bignamini, D; Targher, G; Fargion, S; Fracanzani, Al
NAFLD fibrosis score identifies not only advanced liver fibrosis but also chronic vascular complications in type 2 diabetic patients
2020-01-01 Lombardi, R; Airaghi, L; Targher, G; Serviddio, G; Maffi, G; Mantovani, A; Maffeis, C; Colecchia, A; Villani, R; Rinaldi, L; Orsi, E; Pisano, G; Adinolfi, Le; Fargion, S; Fracanzani, Al
SGLT2 inhibitors improve hepatic fibrosis assessed by Fibroscan in NAFLD patients with type 2 diabetes: a five-year follow-up study
2023-01-01 Lombardi, R; Mantovani, A; Cespiati, A; Maffi, G; Del Zanna, E; Francione, P; Cinque, F; Villani, R; Passigato, N; Orsi, E; Grancini, V; Pisano, G; Maffeis, C; Bignamini, D; Serviddio, G; Targher, G; Fargion, S; Fracanzani, Al
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Evaluation of ChatGPT as a counselling tool for Italian-speaking MASLD patients: assessment of accuracy, completeness and comprehensiveness | 1-gen-2024 | Pugliese, N; Polverini, D; Lombardi, R; Pennisi, G; Ravaioli, F; Armandi, A; Buzzetti, E; Dalbeni, A; Liguori, A; Mantovani, A; Villani, R; Hassan, C; Valenti, L; Miele, L; Petta, S; Sebastiani, G; Aghemo, A | |
| EVOLUTION OF LIVER FIBROSIS IN TYPE 2 DIABETIC PATIENTS WITH NAFLD IN A FOLLOW-UP STUDY: POSSIBLE HEPATOPROTECTIVE EFFECTS OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS | 1-gen-2023 | Lombardi, R; Cespiati, A; Mantovani, A; Maffi, G; Francione, P; Cinque, F; Santomenna, F; Currà, J; Maffeis, C; Colecchia, A; Passigato, N; Ferrarese, A; Cusumanu, Cd; Villani, R; Orsi, E; Grancini, V; Bignamini, D; Targher, G; Fargion, S; Fracanzani, Al | |
| NAFLD fibrosis score identifies not only advanced liver fibrosis but also chronic vascular complications in type 2 diabetic patients | 1-gen-2020 | Lombardi, R; Airaghi, L; Targher, G; Serviddio, G; Maffi, G; Mantovani, A; Maffeis, C; Colecchia, A; Villani, R; Rinaldi, L; Orsi, E; Pisano, G; Adinolfi, Le; Fargion, S; Fracanzani, Al | |
| SGLT2 inhibitors improve hepatic fibrosis assessed by Fibroscan in NAFLD patients with type 2 diabetes: a five-year follow-up study | 1-gen-2023 | Lombardi, R; Mantovani, A; Cespiati, A; Maffi, G; Del Zanna, E; Francione, P; Cinque, F; Villani, R; Passigato, N; Orsi, E; Grancini, V; Pisano, G; Maffeis, C; Bignamini, D; Serviddio, G; Targher, G; Fargion, S; Fracanzani, Al |